CoreLab Partners Now Offers Semi-Automated ECG Solutions
CoreLab Partners, Inc has launched a new semi automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions (A.M.P.S.) LLC.
“We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform,” added Woehler.
The AMPS CalECG application, originally designed for the on-screen measurement of ECG signals in the context of pharmaceutical trials, is capable of handling digital ECGs, interfacing with several types of formats. The recently introduced version 3 of CalECG includes the new powerful measurement algorithm, Bravo, as well as a diagnostic module assisting the user in the determination of important caliper positions.
CoreLab Partners has also licensed the full set of AMPS Heart Rate Variability tools (WinHRV), which has been extensively used in the academic domain for the assessment of autonomic nervous systems changes associated with both clinical and drug-induced conditions.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
